NCT02420691View on ClinicalTrials.gov

Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 25, 2015

Primary Completion Date

June 5, 2019

Study Completion Date

June 5, 2019

Conditions
Advanced Digestive System Neuroendocrine NeoplasmDuodenal Neuroendocrine Tumor G1Functional Pancreatic Neuroendocrine TumorGastric Neuroendocrine TumorIntermediate Grade Lung Neuroendocrine NeoplasmLow Grade Lung Neuroendocrine NeoplasmNonfunctional Pancreatic Neuroendocrine TumorThymus Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Ribociclib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER